Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.

ABSTRACT:

Background and objectives

Patients with diabetes mellitus inject insulin in different regions of the body. This study investigated the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a new-generation once-daily basal insulin with an ultra-long duration of action, after subcutaneous (SC) administration in different injection regions.

Methods

In this study, 20 healthy subjects received single SC doses of IDeg (0.4 U/kg; separated by 13-21 days) in the thigh, abdomen and deltoid in a randomised, open-label, single-centre, single-dose, complete crossover trial. Each dose was followed by a 24-h euglycaemic clamp and 120-h pharmacokinetic blood sampling. The obtained pharmacokinetic/pharmacodynamic profiles were extrapolated to steady state by simulation

SUBMITTER: Nosek L 

PROVIDER: S-EPMC4143594 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature